spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PCI Pharma Services Announces Release of Joint White Paper with Domino on Ink Leachability in Pharmaceutical Serialization

PCI Pharma Services

Important study authored by Domino supports PCI’s Serialization and Aggregation activities

Philadelphia, PA – September 20, 2017 – Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the release of a published white paper detailing Domino’s study which analyzes potential leachability of ink from coding technologies used in pharmaceutical Serialization activities. The study was executed to ensure no migration into drug product contained within HDPE bottles with directly applied codes. Domino is an industry leader in coding and printing technologies operating in over 120 countries worldwide, and one of the key providers of coding technologies to PCI across its global supply network.

The white paper details PCI’s joint development with Domino to analyze potential leachability of coding inks used in the application of Serialized codes directly on HDPE bottles. In the process of Aggregation in Serialization technologies, particularly for high speed bottling lines, it is common industry practice to utilize a second ‘helper’ code, often applied to the bottom of the bottle. Those helper codes are then digitally married to Serialized codes applied to labels on the side of the bottle and assist in line-of-sight verification in the commissioning and Aggregation process. The process of Aggregation establishes a parent-child relationship with the unit of sale and its ancillary packaging, providing numerous benefits in the supply chain. The leachability study was commissioned to ensure proper usage of Domino-supplied inks and compliance with industry requirements in the prevention of ink migration and potential to affect drug product.

The study analyzes several ink types, including both visible black inks as well as invisible fluorescent ink used with ultraviolet (UV) inspection technologies.

PCI’s Ray Hook, Global Serialization Manager, commented: “We collaborated with Domino on this study due to their expertise and global capability for applications like this. As we have progressed our Serialization strategy across our global supply network, it was critical that we identified methods that ensured product safety and security for our clients and the patients using these medicines. Domino provided us with the assurance that we were following industry best practices as we further developed our capability with large scale aggregation activity.”

The study was a key precursor in PCI’s Serialization preparation activities. In February this year, PCI announced a significant capital investment in Serialization capability expansion. The multimillion dollar investment effectively triples PCI’s Serialization capacity in advance of US and EU deadline requirements, with more than 80 installations across PCI’s global supply network. PCI has been providing commercially Serialized drug product to domestic and emerging markets for over five years and is well positioned to support global strategic Serialization and anti-counterfeiting initiatives for its clients.

For more information or to download the Domino white paper, please visit: https://www1.domino-printing.com/en-us/white-papers/domino-and-pci-address-the-issue-of-ink-leachability

phone +44 (0)1495 713 633
email sales@pciservices.com
web www.pciservices.com
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Synpromics expands facilities to meet demand for revolutionary gene control technology

Edinburgh, UK, 11th September 2017 - Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus.
More info >>


White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

Industry Events

11th Annual Proteins & Antibodies Congress

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our esteemed 11thAnnual Proteins & Antibodies Congress 2018, 16th – 17th April 2018, London, UK. Over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement